PortalPublikationenFirst Delayed Resection Findings After Irreversible Electrop...

First Delayed Resection Findings After Irreversible Electroporation (IRE) of Human Localised Renal Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Trial

Standard

First Delayed Resection Findings After Irreversible Electroporation (IRE) of Human Localised Renal Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Trial. / Wendler, Johann Jakob; Ricke, Jens; Pech, Maciej; Fischbach, Frank; Jürgens, Julian; Siedentopf, Sandra; Roessner, Albert; Porsch, Markus; Baumunk, Daniel; Schostak, Martin; Köllermann, Jens; Liehr, Uwe-Bernd.

in: CARDIOVASC INTER RAD, Jahrgang 39, Nr. 2, 02.2016, S. 239-50.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wendler, JJ, Ricke, J, Pech, M, Fischbach, F, Jürgens, J, Siedentopf, S, Roessner, A, Porsch, M, Baumunk, D, Schostak, M, Köllermann, J & Liehr, U-B 2016, 'First Delayed Resection Findings After Irreversible Electroporation (IRE) of Human Localised Renal Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Trial', CARDIOVASC INTER RAD, Jg. 39, Nr. 2, S. 239-50. https://doi.org/10.1007/s00270-015-1200-6

APA

Wendler, J. J., Ricke, J., Pech, M., Fischbach, F., Jürgens, J., Siedentopf, S., Roessner, A., Porsch, M., Baumunk, D., Schostak, M., Köllermann, J., & Liehr, U-B. (2016). First Delayed Resection Findings After Irreversible Electroporation (IRE) of Human Localised Renal Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Trial. CARDIOVASC INTER RAD, 39(2), 239-50. https://doi.org/10.1007/s00270-015-1200-6

Vancouver

Wendler JJ, Ricke J, Pech M, Fischbach F, Jürgens J, Siedentopf S et al. First Delayed Resection Findings After Irreversible Electroporation (IRE) of Human Localised Renal Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Trial. CARDIOVASC INTER RAD. 2016 Feb;39(2):239-50. https://doi.org/10.1007/s00270-015-1200-6

Bibtex

@article{c77c2c9d53fb4007a5a9726db3868d4e,
title = "First Delayed Resection Findings After Irreversible Electroporation (IRE) of Human Localised Renal Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Trial",
abstract = "INTRODUCTION: It is postulated that focal IRE affords complete ablation of soft-tissue tumours while protecting the healthy peritumoral tissue. Therefore, IRE may be an interesting option for minimally invasive, kidney-tissue-sparing, non-thermal ablation of renal tumours.AIM: With this current pilot study ({"}IRENE trial{"}), we present the first detailed histopathological data of IRE of human RCC followed by delayed tumour resection. The aim of this interim analysis of the first three patients was to investigate the ablation efficiency of percutaneous image-guided focal IRE in RCC, to assess whether a complete ablation of T1a RCC and tissue preservation with the NanoKnife system is possible and to decide whether the ablation parameters need to be altered.METHODS: Following resection 4 weeks after percutaneous IRE, the success of ablation and detailed histopathological description were used to check the ablation parameters.RESULTS: The IRE led to a high degree of damage to the renal tumours (1 central, 2 peripheral; size range 15-17 mm). The postulated homogeneous, isomorphic damage was only partly confirmed. We found a zonal structuring of the ablation zone, negative margins and, enclosed within the ablation zone, very small tumour residues of unclear malignancy.CONCLUSION: According to these initial, preliminary study results of the first three renal cases, a new zonal distribution of IRE damage was described and the curative intended, renal saving focal ablation of localised RCC below <3 cm by percutaneous IRE by the NanoKnife system appears to be possible, but needs further, systematic evaluation for this treatment method and treatment protocol.",
keywords = "Ablation Techniques, Biopsy, Carcinoma, Renal Cell, Diagnostic Imaging, Electrocardiography, Electroporation, Female, Germany, Humans, Kidney Neoplasms, Male, Pilot Projects, Tomography, X-Ray Computed, Treatment Outcome, Clinical Trial, Phase II, Journal Article",
author = "Wendler, {Johann Jakob} and Jens Ricke and Maciej Pech and Frank Fischbach and Julian J{\"u}rgens and Sandra Siedentopf and Albert Roessner and Markus Porsch and Daniel Baumunk and Martin Schostak and Jens K{\"o}llermann and Uwe-Bernd Liehr",
year = "2016",
month = feb,
doi = "10.1007/s00270-015-1200-6",
language = "English",
volume = "39",
pages = "239--50",
journal = "CARDIOVASC INTER RAD",
issn = "0174-1551",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - First Delayed Resection Findings After Irreversible Electroporation (IRE) of Human Localised Renal Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Trial

AU - Wendler, Johann Jakob

AU - Ricke, Jens

AU - Pech, Maciej

AU - Fischbach, Frank

AU - Jürgens, Julian

AU - Siedentopf, Sandra

AU - Roessner, Albert

AU - Porsch, Markus

AU - Baumunk, Daniel

AU - Schostak, Martin

AU - Köllermann, Jens

AU - Liehr, Uwe-Bernd

PY - 2016/2

Y1 - 2016/2

N2 - INTRODUCTION: It is postulated that focal IRE affords complete ablation of soft-tissue tumours while protecting the healthy peritumoral tissue. Therefore, IRE may be an interesting option for minimally invasive, kidney-tissue-sparing, non-thermal ablation of renal tumours.AIM: With this current pilot study ("IRENE trial"), we present the first detailed histopathological data of IRE of human RCC followed by delayed tumour resection. The aim of this interim analysis of the first three patients was to investigate the ablation efficiency of percutaneous image-guided focal IRE in RCC, to assess whether a complete ablation of T1a RCC and tissue preservation with the NanoKnife system is possible and to decide whether the ablation parameters need to be altered.METHODS: Following resection 4 weeks after percutaneous IRE, the success of ablation and detailed histopathological description were used to check the ablation parameters.RESULTS: The IRE led to a high degree of damage to the renal tumours (1 central, 2 peripheral; size range 15-17 mm). The postulated homogeneous, isomorphic damage was only partly confirmed. We found a zonal structuring of the ablation zone, negative margins and, enclosed within the ablation zone, very small tumour residues of unclear malignancy.CONCLUSION: According to these initial, preliminary study results of the first three renal cases, a new zonal distribution of IRE damage was described and the curative intended, renal saving focal ablation of localised RCC below <3 cm by percutaneous IRE by the NanoKnife system appears to be possible, but needs further, systematic evaluation for this treatment method and treatment protocol.

AB - INTRODUCTION: It is postulated that focal IRE affords complete ablation of soft-tissue tumours while protecting the healthy peritumoral tissue. Therefore, IRE may be an interesting option for minimally invasive, kidney-tissue-sparing, non-thermal ablation of renal tumours.AIM: With this current pilot study ("IRENE trial"), we present the first detailed histopathological data of IRE of human RCC followed by delayed tumour resection. The aim of this interim analysis of the first three patients was to investigate the ablation efficiency of percutaneous image-guided focal IRE in RCC, to assess whether a complete ablation of T1a RCC and tissue preservation with the NanoKnife system is possible and to decide whether the ablation parameters need to be altered.METHODS: Following resection 4 weeks after percutaneous IRE, the success of ablation and detailed histopathological description were used to check the ablation parameters.RESULTS: The IRE led to a high degree of damage to the renal tumours (1 central, 2 peripheral; size range 15-17 mm). The postulated homogeneous, isomorphic damage was only partly confirmed. We found a zonal structuring of the ablation zone, negative margins and, enclosed within the ablation zone, very small tumour residues of unclear malignancy.CONCLUSION: According to these initial, preliminary study results of the first three renal cases, a new zonal distribution of IRE damage was described and the curative intended, renal saving focal ablation of localised RCC below <3 cm by percutaneous IRE by the NanoKnife system appears to be possible, but needs further, systematic evaluation for this treatment method and treatment protocol.

KW - Ablation Techniques

KW - Biopsy

KW - Carcinoma, Renal Cell

KW - Diagnostic Imaging

KW - Electrocardiography

KW - Electroporation

KW - Female

KW - Germany

KW - Humans

KW - Kidney Neoplasms

KW - Male

KW - Pilot Projects

KW - Tomography, X-Ray Computed

KW - Treatment Outcome

KW - Clinical Trial, Phase II

KW - Journal Article

U2 - 10.1007/s00270-015-1200-6

DO - 10.1007/s00270-015-1200-6

M3 - SCORING: Journal article

C2 - 26341653

VL - 39

SP - 239

EP - 250

JO - CARDIOVASC INTER RAD

JF - CARDIOVASC INTER RAD

SN - 0174-1551

IS - 2

ER -